MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Boston Scientific to deal microspheres to Varian Medical for $90m

Boston Scientific to deal microspheres to Varian Medical for $90m

By

Boston Scientific acquires BTGUPDATED July 2, 2019, with financial details, comment from Varian.

Looking to mollify anti-trust regulators about its pending $4 billion merger with BTG (LON:BTG), Boston Scientific (NYSE:BSX) said today that it agreed to deal its microsphere assets to Varian Medical (NYSE:VAR) for $90 million.

The deal for the drug-eluting and “bland” embolic microsphere business includes Marlborough, Mass.-based Boston Scientific’s Oncozene, Embozene and Embozone Tandem products, which put up sales of $21.2 million last year. The sale is slated to close after Boston and BTG conclude their merger in August.

Regulators in Germany cleared the BTG-Boston tie-up and Taiwan’s Fair Trade Commission closed its look at the deal, Boston and BTG said.

“This acquisition from Boston Scientific will strengthen Varian’s growing position in the high-value interventional oncology segment and is consistent with our long-term strategy to become a global leader in multidisciplinary, integrated cancer solutions,” Varian president & CEO Dow Wilson said in prepared remarks. “We look forward to completing this acquisition and are excited to add these drug-loadable microsphere and bland embolic bead products to our portfolio to provide our clinical partners with expanded advanced treatment options.”

Varian said the microsphere buyout, which does not include any Boston Scientific operations, is not expected to affect its fiscal year 2019 results but to add to both reported earnings and adjusted earnings in fiscal 2020.

“While Varian implements a plan to manufacture and distribute these products, it will work with Boston Scientific under transition services agreements to ensure uninterrupted delivery to customers,” the company said.

BTG’s shareholders in March OK’d the transaction, which calls for Boston Scientific to put up £8.40 per share or about $4.24 billion (£3.3 billion). Also in March, Boston Scientific closed a $4.3 billion debt round it plans use to defray the cost of buying BTG.

BTG’s largest division makes devices for oncology and vascular conditions; the company also makes overdose and antivenin drugs for snakebite.

In case you missed it

RSS From Medical Design & Outsourcing

  • Wytech Industries names new president
    Specialty and precision wire manufacturer Wytech Industries (Rahway, N.J.) today announced it has named David Ohmann as president. Ohmann has nearly 25 years of experience in international, orthopedic and advanced surgical medical device segments. Prior to joining Wytech, Ohmann held sales and marketing leadership positions at Heraeus and MicroGroup (a TE Connectivity company). Ohmann has a… […]
  • Spectrum Plastics acquires Laser Light Technologies
    Spectrum Plastics Group has announced the acquisition of substantially all assets of Laser Light Technologies. An ISO 9001- and ISO 13485-certified organization based in Hermann, Mo., Laser Light Technologies provides custom laser processing systems and services using excimer, femtosecond, picosecond and YAG laser technologies. “The addition of the talented team at Laser Light Technologies brings… […]
  • Dymax announces deal with coatings company
    Dymax and nanocoatings manufacturer HZO today announced a strategic partnership. The deal will add 3,000 coatings formulations to HZO’s portfolio, facilitate joint product development, and use Dymax’s global sales channel to extend market reach. Dymax (Torrington, Conn.) manufactures rapid light-cure adhesives, conformal coatings, potting compounds and complementary dispensing and curing equipment used in medtech and… […]
  • Qosina releases 2022 catalog
    Qosina said today it has released the latest edition of its product catalog in both print and digital formats. The 2022 product catalog includes thousands of single-use medical and pharma components depicted in full-scale photos on a one-centimeter grid to help design engineers visualize their next-generation medical device, according to the Ronkonkoma, N,.Y.-based company. Qosina… […]
  • Medline completes $1.5B spending plan
    Medline Industries announced this week that it has completed a three-year, $1.5 billion capital spending campaign. The Northfield, Ill.-based company, which is reportedly up for sale, said it invested the money in new distribution centers, manufacturing capabilities and IT upgrades to improve customers’ e-commerce experience. All told, the initiative added approximately 8,500 new jobs, eight… […]
  • Clippard touts flow controller with high resolution and repeatability in a closed-loop system
    Clippard recently announced the release of its Cordis flow controller, which uses a MEMS technology sensor upstream from a proportional valve. There’s also an option for a DR-2 regulator to provide accurate and precise pressure control in a small package. Said Clippard: “Unlike other mass flow controllers that require a 30-minute warm-up time, large differential… […]
  • FDA clears DBS targeting software
    Surgical Information Sciences (SIS) recently won FDA clearance for software designed to guide deep-brain stimulation (DBS) procedures. The Plymouth, Minn.-based company’s software uses deep learning models to identify brain structures such as the subthalamic nuclei (STN) and globus pallidus internus/externus (GPi/GPe) commonly targeted for DBS procedures. The SIS system provides visualization of these structures for… […]
  • Cerapedics’ bone graft gains FDA breakthrough nod
    Ortho-biologics company Cerapedics announced that it has won FDA breakthrough device designation for its investigational P-15L bone graft to treat degenerative disc disease (DDD). The company plans to enroll at least 270 DDD patients in the Aspire study, a prospective, single-blinded, multi-center, randomized, non-inferiority pivotal IDE study to evaluate the safety and efficacy of P-15L… […]
  • FDA revokes Battelle mask decontamination EUA
    The FDA has revoked its authorization for Battelle Memorial Institute to decontaminate used N95 respirators for healthcare workers. In a letter dated April 30, 2021, the agency said it revoked the EUA at Battelle’s request. The Columbus, Ohio-based research organization asked to withdraw the EUA for its Critical Care Decontamination System (CCDS) in an April… […]
  • The importance of a valve’s soft start for critical applications requiring high precision
    When a valve is cycled, one can observe the quality of control by measuring and graphing the flow leaving the valve and the input operating the valve, such as electrical current (for coil controlled valves) or steps (for stepper motor controlled valves). This paper will discuss the characteristics of a valve’s performance curve—specifically, where flow… […]
  • 5 IP tips for medical device entrepreneurs
    Taking certain steps — including some that are easily overlooked — can better protect your intellectual property. Thinking of designing your own medical device or launching a company? In recent DeviceTalks Weekly podcasts, two partners from the intellectual property law firm Finnegan, Henderson, Farabow, Garrett & Dunner, LLP shared several tips medical device company executives… […]